Frequency of vaccine-related reactogenicity events During inpatient stage [clinicaltrials_resource:bbc432e3b27b025941f5a385b84c23f1]
Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Frequency of vaccine-related reactogenicity events During inpatient stage [clinicaltrials_resource:bbc432e3b27b025941f5a385b84c23f1]
Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
Bio2RDF identifier
bbc432e3b27b025941f5a385b84c23f1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bbc432e3b27b025941f5a385b84c23f1
measure [clinicaltrials_vocabulary:measure]
Frequency of vaccine-related reactogenicity events
time frame [clinicaltrials_vocabulary:time-frame]
During inpatient stage
description
Participants will receive 0.5 ...... vice (0.25 mL in each nostril)
identifier
clinicaltrials_resource:bbc432e3b27b025941f5a385b84c23f1
title
Frequency of vaccine-related reactogenicity events During inpatient stage
@en
type
label
Frequency of vaccine-related r ...... 432e3b27b025941f5a385b84c23f1]
@en